204 related articles for article (PubMed ID: 22617224)
21. Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Torp-Pedersen C; Køber L; Poulsen HE
Pharmacogenet Genomics; 2012 Oct; 22(10):709-15. PubMed ID: 22760495
[TBL] [Abstract][Full Text] [Related]
22. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
23. Does atrial fibrillation in elderly patients with chronic heart failure limit the efficacy of carvedilol? Suggestions from an observational study.
Opasich C; De Feo S; Cioffi G; Pulignano G; Del Sindaco D; Tarantini L; Gualco A; Patrignani A
Ital Heart J; 2005 Apr; 6(4):323-7. PubMed ID: 15902931
[TBL] [Abstract][Full Text] [Related]
24. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
Piccini JP; Connolly SJ; Abraham WT; Healey JS; Steinberg BA; Al-Khalidi HR; Dignacco P; van Veldhuisen DJ; Sauer WH; White M; Wilton SB; Anand IS; Dufton C; Marshall DA; Aleong RG; Davis GW; Clark RL; Emery LL; Bristow MR
Am Heart J; 2018 May; 199():51-58. PubMed ID: 29754666
[TBL] [Abstract][Full Text] [Related]
25. Regional differences among female patients with heart failure from the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD).
Apostolovic S; Stanojevic D; Lainscak M; Gelbrich G; Jankovic-Tomasevic R; Pavlovic M; Djordjevic-Radojkovic D; Salinger-Martinovic S; Putnikovic B; Radovanovic S; Waagstein F; Tomasevic M; Tahirovic E; Inkrot S; Musial-Bright L; Düngen HD
Cardiol J; 2014; 21(3):265-72. PubMed ID: 23990195
[TBL] [Abstract][Full Text] [Related]
26. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
[TBL] [Abstract][Full Text] [Related]
27. Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure.
Hamaad A; Lip GY; Nicholls D; MacFadyen RJ
Cardiovasc Drugs Ther; 2007 Dec; 21(6):437-44. PubMed ID: 17896170
[TBL] [Abstract][Full Text] [Related]
28. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?
Agostoni P; Contini M; Cattadori G; Apostolo A; Sciomer S; Bussotti M; Palermo P; Fiorentini C
Eur J Heart Fail; 2007 Aug; 9(8):827-33. PubMed ID: 17561440
[TBL] [Abstract][Full Text] [Related]
29. Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Taniguchi T; Ohtani T; Mizote I; Kanzaki M; Ichibori Y; Minamiguchi H; Asano Y; Sakata Y; Komuro I
J Cardiol; 2013 Jun; 61(6):417-22. PubMed ID: 23548374
[TBL] [Abstract][Full Text] [Related]
30. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
31. Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure.
Konishi M; Haraguchi G; Kimura S; Inagaki H; Kawabata M; Hachiya H; Hirao K; Isobe M
Circ J; 2010 Jun; 74(6):1127-34. PubMed ID: 20354334
[TBL] [Abstract][Full Text] [Related]
32. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
[TBL] [Abstract][Full Text] [Related]
33. [Impact of Gly389Arg beta1-adrenoceptor polymorphism on the risk of chronic heart failure, the nature of its course, and on the efficiency of its treatment with carvedilol].
Tepliakov AT; Shilov SN; Berezikova EN; Torim IuIu; Efremov AV; Safronov ID; Maianskaia SD; Popova AA; Voronina EN; Karpov RS
Ter Arkh; 2010; 82(12):22-8. PubMed ID: 21516734
[TBL] [Abstract][Full Text] [Related]
34. Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?
Cioffi G; De Feo S; Pulignano G; Del Sindaco D; Tarantini L; Stefenelli C; Opasich C
Int J Cardiol; 2006 Feb; 107(2):220-4. PubMed ID: 16412800
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats.
Willette RN; Aiyar N; Yue TL; Mitchell MP; Disa J; Storer BL; Naselsky DP; Stadel JM; Ohlstein EH; Ruffolo RR
J Pharmacol Exp Ther; 1999 Apr; 289(1):48-53. PubMed ID: 10086986
[TBL] [Abstract][Full Text] [Related]
36. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity.
Bruck H; Leineweber K; Temme T; Weber M; Heusch G; Philipp T; Brodde OE
J Am Coll Cardiol; 2005 Dec; 46(11):2111-5. PubMed ID: 16325050
[TBL] [Abstract][Full Text] [Related]
37. The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β(1) adrenergic receptor antagonist esmolol in healthy individuals.
Muszkat M; Hoofien A; Orlanski-Meyer E; Makhoul H; Porat E; Davidson EM; Blotnick S; Caraco Y
Pharmacogenet Genomics; 2013 Jan; 23(1):25-8. PubMed ID: 23114278
[TBL] [Abstract][Full Text] [Related]
38. Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study.
Yamashita T; Inoue H
J Cardiol; 2013 Jul; 62(1):50-7. PubMed ID: 23611172
[TBL] [Abstract][Full Text] [Related]
39. The effects of 2 beta-receptor blocking agents on the microcirculation of healthy subjects and of hypertensive patients.
Albrecht M; Haustein KO
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):580-6. PubMed ID: 9455718
[TBL] [Abstract][Full Text] [Related]
40. Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation.
Nia AM; Caglayan E; Gassanov N; Zimmermann T; Aslan O; Hellmich M; Duru F; Erdmann E; Rosenkranz S; Er F
PLoS One; 2010 Jul; 5(7):e11421. PubMed ID: 20625396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
